SAGIMET BIOSCIENCES INC. - SERIES A COMMON STOCK

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

23 أبريل 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

12 مارس 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

11 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

19 فبراير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

06 يناير 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

18 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

14 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

07 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

29 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

16 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

11 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

01 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أكتوبر 2024 00:05:00 بحسب Nasdaq GlobeNewswire

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

12 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

04 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

14 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

01 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat 

10 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

06 يونيو 2024 05:00:00 بحسب Nasdaq GlobeNewswire